Drug-Receptor Interactions and Binding

A drug-receptor interaction is the reversible (or sometimes covalent) binding of a drug molecule to a specific macromolecular receptor, the event that initiates pharmacological action. The chemistry of this binding - its affinity, its molecular complementarity, and the conformational change it produces - determines whether a drug behaves as an agonist, an antagonist, or a modulator, and how potent it is.

Definition

A drug-receptor interaction is the binding of a drug (ligand) to a specific receptor macromolecule, characterised by an affinity (the equilibrium dissociation constant, Kd) and an intrinsic efficacy that together determine the pharmacological response.

Scope

This topic covers the physicochemical basis of drug binding to receptors: affinity and the equilibrium dissociation constant, the mass-action (occupancy) description of binding, the distinction between affinity and efficacy, the types of ligand (agonist, antagonist, partial and inverse agonist), and the binding parameters used to quantify these interactions. It is a mechanistic, reference entry and does not address dosing or therapy selection.

Core questions

• How tightly does a drug bind its receptor, and how is that affinity measured?
• What is the difference between affinity and efficacy?
• How does the law of mass action describe receptor occupancy?
• What types of ligand-receptor relationship exist (agonist, antagonist, partial, inverse)?
• How do competitive and non-competitive binding differ in their effect on response?

Key concepts

• Affinity and the dissociation constant (Kd)
• Law of mass action and receptor occupancy
• Efficacy and intrinsic activity
• Agonist, antagonist, partial agonist, inverse agonist
• Competitive versus non-competitive binding
• Allosteric versus orthosteric sites
• Radioligand binding and Kd/Bmax estimation

Key theories

Occupancy theory of drug action

Response is related to the fraction of receptors a drug occupies, described by mass-action equilibrium between free drug, free receptor, and the drug-receptor complex; this yields affinity (Kd) as a fundamental binding parameter.

Operational model (affinity vs efficacy)

Black and Leff formalised the separation of a ligand's binding affinity from its efficacy - the capacity to produce response once bound - so that two drugs of equal affinity can differ in maximal effect, explaining partial agonism quantitatively.

Mechanisms

Binding is driven by complementary molecular interactions - hydrogen bonds, ionic and hydrophobic contacts, and shape complementarity - between the drug and a defined site on the receptor. Under the law of mass action, free drug and free receptor associate to form a drug-receptor complex, and the equilibrium dissociation constant (Kd) measures the affinity of the interaction. Occupancy of the receptor is necessary but not sufficient for effect: the drug's intrinsic efficacy determines how much response a given level of occupancy produces, which is why the operational model of Black and Leff separates affinity from efficacy. Agonists bind and activate; antagonists bind without activating and block agonist access (competitively) or alter the receptor non-competitively; partial agonists produce a submaximal effect; inverse agonists reduce constitutive activity. Allosteric ligands bind a site distinct from the endogenous (orthosteric) site and tune the response, a mechanism central to modern receptor pharmacology.

Clinical relevance

Binding affinity and efficacy explain why drugs acting on the same receptor differ in potency and in whether they activate or block it, and they underlie how candidate molecules are characterised and optimised in medicinal chemistry. The content here is mechanistic and educational and does not constitute prescribing or dosing guidance.

Evidence & guidelines

Quantitative binding terms (affinity, Kd, efficacy, agonist and antagonist definitions) follow the standardised IUPHAR nomenclature; the Cheng-Prusoff relationship is the conventional method for converting an inhibitory IC50 to an affinity constant in competition binding.

History

The receptor idea originated with Langley and Ehrlich, and A. J. Clark applied the law of mass action to quantify drug action in the 1920s-1930s. Stephenson introduced the concept of efficacy in 1956 to explain partial agonism, and Black and Leff's 1983 operational model united affinity and efficacy in a single quantitative framework that remains standard.

Debates

Does receptor occupancy predict drug effect?

Classical occupancy theory ties response to the fraction of receptors bound, but the need to invoke efficacy and 'spare receptors' shows that occupancy alone is an incomplete predictor; the operational model reconciles binding with the observed concentration-effect relationship.

Key figures

• James Black
• Paul Leff
• Terry Kenakin
• Robert Stephenson

Seminal works

• black-leff-1983
• neubig-2003
• cheng-prusoff-1973

Frequently asked questions

What is the difference between affinity and efficacy?

Affinity describes how tightly a drug binds its receptor (captured by the dissociation constant Kd), while efficacy describes how effectively the drug produces a response once bound. Two drugs can share the same affinity yet differ in efficacy, as with a partial versus a full agonist.

What is a competitive antagonist?

A competitive antagonist binds the same site as the agonist without activating the receptor, so it can be overcome by raising the agonist concentration; this shifts the agonist concentration-response curve to the right.